BX004-A first-in-human trial
A first-in-human, double-blind, placebo-controlled phase 1b/2a trial evaluated nebulized three-phage cocktail BX004-A in nine adults with cystic fibrosis and chronic Pseudomonas aeruginosa infection. The trial met its primary safety and tolerability endpoints.
Topics
| Source | Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial |
|---|